moxibustion
OtherThe experimental group received moxibustion of Zhongji, Guanyuan, and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation, while treated conventionally.
NCT Number: NCT06198517
This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine tests were performed once every 7 days for all patients within 100days. For patients with Hemorrhagic cystitis (HC), daily severity grading, pain scoring, cystitis symptom scoring, use of antispasmodic and analgesic medications, and major TCM evidence were recorded with the aim of evaluating the efficacy of moxibustion in the prevention of HC in this patient population.
Interested in participating?
Request Info14 year–60 year
All sexes
Interventional
Not applicable
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Zhengzhou, Henan, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The experimental group received moxibustion of Zhongji, Guanyuan, and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation, while treated conventionally.
The control group received conventional symptomatic treatment.
Time frame: 100 days
highest pain score in HC patients within 100 days of transplantation
Time frame: 100 days
Weighted Pain Score (WPS) is a method used to assess the overall pain burden by considering both the intensity and the duration of pain. Steps to Calculate WPS:
Record Pain Intensity : Measure the patient's pain at various time points during the study or treatment.
Determine Time Intervals : Record the duration for which the pain was experienced at each time point.
Assign Weights : Weights are typically assigned based on the clinical significance of the time period. For example, if a patient experiences severe pain for a prolonged period, that period would have a higher weight.
Calculate the WPS: Multiply the pain intensity by the duration and the weight for each time period, and sum all these values to get the total WPS.
Time frame: 100 days
Time frame: 100 days
Time frame: 100 days
Time frame: 100 days
Time frame: 100 days
Time frame: 100 days
Time frame: 100 days
Contact information is provided by the study sponsor or research team.
Yi Zhang
Other
Clinical Study of Moxibustion for the Prevention of Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06241274
Cystitis, Cystitis, Hemorrhagic
Wuhan, Hubei, China
View Trial DetailsNCT07598227
Acupoint, Lower Urinary Tract Symptoms
Hualien City, Taiwan
View Trial DetailsNCT06330233
Diabetic Peripheral Neuropathy, Moxibustion
Hangzhou, Zhejiang, China
View Trial DetailsNCT05726786
Bladder Cancer, Bladder Disease
Lausanne, Canton of Vaud, Switzerland
View Trial Details